Age-dependent development of metabolic derangement and effects of intervention with pioglitazone in zucker diabetic fatty rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 323-329

  Szöcs, Zsuzsanna ^a   Brunmair, Barbara ^a   Stadlbauer, Karin ^a   Nowotny, Peter ^a   Bauer, Leonhardt ^b   Luger, Anton ^a   Fürnsinn, Clemens ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b 55Pharma Drug Discovery and Development AG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; GLYCOGEN; INSULIN; LIPID; PIOGLITAZONE; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLYCOGEN MUSCLE LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SKELETAL MUSCLE; STEADY STATE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ZUCKER DIABETIC FATTY RAT;

AGING; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES;

EID: 45749085276     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.136465     Document Type: Article

References (40)

1. Anderwald C, Brunmair B, Stadlbauer K, Krebs M, Fürnsinn C, and Roden M (2007) Effects of free fatty acids on carbohydrate metabolism and insulin signalling in perfused rat liver. Eur J Clin Invest 37:774-782.
2. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83.
3. Bays H, Mandarino L, and DeFronzo RA (2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferators-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478.
4. Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye J-M, Sauerberg P, and Wassermann K (2003) Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab 284:E841-E854.
5. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhäusl W, et al. (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059.
6. Carey PE, Halliday J, Snaar JEM, Morris PG, and Taylor R (2003) Direct assessment of muscle glycogen storage after mixed meals in normal and type 2 diabetic subjects. Am J Physiol Endocrinol Metab 284:E688-E694.
7. Cho DH, Choi YJ, Jo SA, Ryou J, Kim JY, Chung J, and Jo I (2006) Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition. Am J Physiol Cell Physiol 291:C317-C326.
8. Clark JB, Palmer CJ, and Shaw WN (1983) The Zucker diabetic fatty rat. Proc Soc Exp Biol Med 173:68-75.
9. DeFronzo RA (1988) The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687.
10. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, and Thomas G (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294:1102-1105.
11. Erdely A, Freshour G, Maddox DA, Olson JL, Samsell L, and Baylis C (2004) Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production. Diabetologia 47:1672-1676.
12. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, and Buckingham RE (2001) β-Cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-1029.
13. Han SW and Roman J (2006) Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol Cancer Ther 5:430-437.
14. He G, Sung YM, DiGiovanni J, and Fischer SM (2006) Thiazolidinediones inhibit insulin-like growth factor-I-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 66:1873-1879.
15. He J and Kelley DE (2004) Muscle glycogen content in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 287:E1002-E1007.
16. 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 95:783-787.
17. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill C, Zinman B, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2444.
18. Khamzina L, Veilleux A, Bergeron S, and Marette A (2005) Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 146:1473-1481.
19. Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P, Roth E, Fürnsinn C, Promintzer M, Anderwald C, et al. (2007) The mammalian target of Rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 56:1600-1607.
20. Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Dalla Man C, Cobelli C, Cline GW, Shulman GI, Waldhäusl W, et al. (2004) Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53:3048-3056.
21. Laurent D, Hundal RS, Dresner A, Price TB, Vogel SM, Petersen KF, and Shulman GI (2000) Mechanism of muscle glycogen autoregulation in humans. Am J Physiol Endocrinol Metab 278:E663-E668.
22. LeBrasseur NK, Kelley M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, and Thomas E (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 291:E175-E181.
23. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, and DeFronzo RA (2004) Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89:4312-4319.
24. Nesto RW, Bell D, and Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108:2941-2948.
25. Nielsen JN, Derave W, Kristiansen S, Ralston E, Plough T, and Richter EA (2001) Glycogen synthase localization and activity in rat skeletal muscle is strongly dependent on glycogen content. J Physiol 531:757-769.
26. Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471.
27. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CT, and Hess JF (1996) Leptin receptor missense mutation in the fatty Zucker rat. Nature Genet 13:18-19.
28. Pickavance LC, Brand CL, Wassermann K, and Wilding JPH (2005) The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 144:308-316.
29. Randle PJ (1998) Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14:263-283.
30. Roden M (2004) How free fatty acids inhibit glucose utilization in human skeletal muscle. News Physiol Sci 19:92-96
31. Saha AK, Avilucea P, Ye JM, Assifi MM, Kraegen EW, and Ruderman NB (2004) Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314:580-585.
32. Smith SA (2003) Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of thiazolidinediones. Biochimie 85:1219-1230.
33. Smith SA, Lister CA, Toseland CDN, and Buckingham RE (2000) Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2:363-372.
34. Sturis J, Pugh WL, Tang J, and Polonsky KS (1995) Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF rat. Am J Physiol Endocrinol Metab 269:E786-E792.
35. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105.
36. UK Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258.
37. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, et al. (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-205.
38. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, and Prins JB (2006) Adiponectin: a key adipokine in the metabolic syndrome. Diabetes Obes Metab 8:264-280.
39. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1294.
40. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, Winegar DA, Strum JC, Stimpson SA, and Pahel GL (2004) Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 4:23.